These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37242713)

  • 1. Investigation of
    Park YD; Chae YJ; Maeng HJ
    Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amifampridine for the Management of Lambert-Eaton Myasthenic Syndrome: A New Take on an Old Drug.
    Yoon CH; Owusu-Guha J; Smith A; Buschur P
    Ann Pharmacother; 2020 Jan; 54(1):56-63. PubMed ID: 31319693
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
    Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
    Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amifampridine to treat Lambert-Eaton myasthenic syndrome.
    Oh SJ
    Drugs Today (Barc); 2020 Oct; 56(10):623-641. PubMed ID: 33185628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amifampridine for the treatment of Lambert-Eaton myasthenic syndrome.
    Oh SJ
    Expert Rev Clin Immunol; 2019 Oct; 15(10):991-1007. PubMed ID: 31533480
    [No Abstract]   [Full Text] [Related]  

  • 6. Amifampridine tablets for the treatment of Lambert-Eaton myasthenic syndrome.
    Mantegazza R
    Expert Rev Clin Pharmacol; 2019 Nov; 12(11):1013-1018. PubMed ID: 31639317
    [No Abstract]   [Full Text] [Related]  

  • 7. Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate.
    Haroldsen PE; Garovoy MR; Musson DG; Zhou H; Tsuruda L; Hanson B; O'Neill CA
    Pharmacol Res Perspect; 2015 Feb; 3(1):e00099. PubMed ID: 25692017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tissue distribution of 3,4-diaminopyridine in rats.
    Ishida N; Kondo Y; Chikano Y; Kobayashi-Nakade E; Suga Y; Ishizaki J; Komai K; Matsushita R
    Biopharm Drug Dispos; 2019 Sep; 40(8):294-301. PubMed ID: 31419315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylator Status Impacts Amifampridine Phosphate (Firdapse™) Pharmacokinetics and Exposure to a Greater Extent Than Renal Function.
    Haroldsen PE; Sisic Z; Datt J; Musson DG; Ingenito G
    Clin Ther; 2017 Jul; 39(7):1360-1370. PubMed ID: 28641995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromuscular junction disorders beyond myasthenia gravis.
    Oh SJ
    Curr Opin Neurol; 2021 Oct; 34(5):648-657. PubMed ID: 34914667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amifampridine Phosphate (Firdapse) Is Effective in a Confirmatory Phase 3 Clinical Trial in LEMS.
    Shieh P; Sharma K; Kohrman B; Oh SJ
    J Clin Neuromuscul Dis; 2019 Mar; 20(3):111-119. PubMed ID: 30801481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.
    Oh SJ; Shcherbakova N; Kostera-Pruszczyk A; Alsharabati M; Dimachkie M; Blanco JM; Brannagan T; Lavrnić D; Shieh PB; Vial C; Meisel A; Komoly S; Schoser B; Sivakumar K; So Y;
    Muscle Nerve; 2016 May; 53(5):717-25. PubMed ID: 26852139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetaminophen is an inhibitor of hepatic N-acetyltransferase 2 in vitro and in vivo.
    Rothen JP; Haefeli WE; Meyer UA; Todesco L; Wenk M
    Pharmacogenetics; 1998 Dec; 8(6):553-9. PubMed ID: 9918139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine.
    Lindquist S; Stangel M
    Neuropsychiatr Dis Treat; 2011; 7():341-9. PubMed ID: 21822385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances and Therapeutic Options in Lambert-Eaton Myasthenic Syndrome.
    Anwar A; Saleem S; Ahmed MF; Ashraf S; Ashraf S
    Cureus; 2019 Aug; 11(8):e5450. PubMed ID: 31637147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).
    Sanders DB
    Ann N Y Acad Sci; 1998 May; 841():811-6. PubMed ID: 9668334
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.
    Smith AG; Wald J
    Neurology; 1996 Apr; 46(4):1143-5. PubMed ID: 8780107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment for Lambert-Eaton myasthenic syndrome.
    Keogh M; Sedehizadeh S; Maddison P
    Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD003279. PubMed ID: 21328260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.
    Molgó J; Guglielmi JM
    Pflugers Arch; 1996; 431(6 Suppl 2):R295-6. PubMed ID: 8739381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment for Lambert-Eaton myasthenic syndrome.
    Maddison P; Newsom-Davis J
    Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.